Literature DB >> 30481999

Hemadsorption during cardiopulmonary bypass reduces interleukin 8 and tumor necrosis factor α serum levels in cardiac surgery: a randomized controlled trial.

Ingo Garau1, Alexander März2, Susanne Sehner3, Daniel A Reuter2, Hermann Reichenspurner4, Christian Zöllner1, Jens C Kubitz5.   

Abstract

BACKGROUND: Surgical trauma and cardiopulmonary bypass (CPB) are associated with the liberation of pro-inflammatory cytokines. With hemadsorption (Cytosorb®) during CPB, pro-inflammatory cytokines may be reduced and the inflammatory response may be decreased.
METHODS: In this prospective, randomized single center study, serum cytokine levels of interleukin 8 (Il-8), interleukin 6 (Il-6) and tumor-necrosis-factor α (TNFα) were assessed in elective on-pump cardiac surgery patients with hemadsorption on CPB (study group [SG], N.=20) and without (control group [CG], N.=20). Cytokine levels were assessed prior to CPB, at the end of CPB, and 6 hours (h) and 24 h after the end of CPB, together with a hemodynamic assessment. Cardiac-Index (CI) was assessed with transcardiopulmonary thermodilution.
RESULTS: For Il-8, significantly lower serum levels were observed in the SG compared to the CG at the end of CPB (P=0.008). In the SG, TNFα levels were also below those in the CG at both the end of and 6h after CPB (P=0.034). After 24 hours, TNFα levels were at baseline in both groups. No significant differences were found for Il-6. The CI was significantly higher in the SG at the end of CPB (P=0.025). However, there was no difference between both groups 6 h after CPB.
CONCLUSIONS: This prospective study shows a significant reduction in pro-inflammatory cytokine levels of Il-8 and TNFα with hemadsorption in on-pump cardiac surgery whilst also demonstrating safety in its applications. However, the differences in cytokine levels and CI between patients treated with hemadsorption and those without were minor and of short duration.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30481999     DOI: 10.23736/S0375-9393.18.12898-7

Source DB:  PubMed          Journal:  Minerva Anestesiol        ISSN: 0375-9393            Impact factor:   3.051


  5 in total

1.  Use of CytoSorb® hemoadsorption column during prolonged cardiopulmonary bypass in complex cardiac surgery patient.

Authors:  Marianne Alarie; Maggie Savelberg; Danika Vautour; Igo B Ribeiro
Journal:  J Cardiothorac Surg       Date:  2022-07-07       Impact factor: 1.522

Review 2.  Application of Adsorptive Blood Purification Techniques during Cardiopulmonary Bypass in Cardiac Surgery.

Authors:  Meng-Han Liu; Hong Yu; Rong-Hua Zhou
Journal:  Oxid Med Cell Longev       Date:  2022-05-25       Impact factor: 7.310

3.  Intraoperative hemoadsorption in high-risk patients with infective endocarditis.

Authors:  Zaki Haidari; Ender Demircioglu; Kristina Boss; Bartosz Tyczynski; Matthias Thielmann; Bastian Schmack; Andreas Kribben; Alexander Weymann; Mohamed El Gabry; Arjang Ruhparwar; Daniel Wendt
Journal:  PLoS One       Date:  2022-07-28       Impact factor: 3.752

Review 4.  Mortality and adverse events of hemoadsorption with CytoSorb® in critically ill patients: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Marc Heymann; Raoul Schorer; Alessandro Putzu
Journal:  Acta Anaesthesiol Scand       Date:  2022-07-18       Impact factor: 2.274

5.  Extracorporeal Hemadsorption versus Glucocorticoids during Cardiopulmonary Bypass: A Prospective, Randomized, Controlled Trial.

Authors:  Gordana Taleska Stupica; Maja Sostaric; Marija Bozhinovska; Lea Rupert; Zoran Bosnic; Ales Jerin; Alojz Ihan; Tomislav Klokocovnik; Matej Podbregar
Journal:  Cardiovasc Ther       Date:  2020-03-27       Impact factor: 3.023

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.